1. First documented outbreak of KPC-2-producing Klebsiella pneumoniae in Switzerland: infection control measures and clinical management.
- Author
-
Lemmenmeier E, Kohler P, Bruderer T, Goldenberger D, Kleger GR, and Schlegel M
- Subjects
- Adult, Aged, Anti-Bacterial Agents therapeutic use, Colistin therapeutic use, Electrophoresis, Gel, Pulsed-Field, Genotype, Humans, Intensive Care Units, Klebsiella Infections pathology, Klebsiella Infections prevention & control, Klebsiella pneumoniae classification, Klebsiella pneumoniae enzymology, Klebsiella pneumoniae genetics, Male, Meropenem, Middle Aged, Minocycline analogs & derivatives, Minocycline therapeutic use, Molecular Typing, Switzerland epidemiology, Tertiary Care Centers, Thienamycins therapeutic use, Tigecycline, Treatment Outcome, beta-Lactamases genetics, Disease Outbreaks, Infection Control methods, Klebsiella Infections epidemiology, Klebsiella Infections microbiology, Klebsiella pneumoniae isolation & purification, beta-Lactamases metabolism
- Abstract
We report the epidemiological and clinical features of the first outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) type 2 in Switzerland. The outbreak took place in the medical intensive care unit (MICU) of our tertiary care hospital and affected three severely ill patients. After the implementation of strict infection control measures, no further patients colonised with KPC-KP could be detected by the screening of exposed patients. Successful treatment of patients infected with KPC-KP consisted of a combination therapy of meropenem, colistin and tigecycline.
- Published
- 2014
- Full Text
- View/download PDF